The acute psychotomimetic effect of cannabis is transitory, but evidence indicates that the chronic use, especially if started in adolescence, contributes to the occurrence of schizophrenia.
Antonio Waldo Zuardi, MD, PhD
Advertisement
Articles by Antonio Waldo Zuardi, MD, PhD
Drs Zuardi and Crippa discuss the current stage of scientific evidence that supports the use of cannabidiol in schizophrenia, anxiety, and Parkinson disease.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Accepts NDA for CTx-1301 for Treatment of ADHD
2
Treating Mental Illness During Pregnancy the Same as Any Medical Illness: In Conversation With Jennifer L. Payne, MD
3
The Use of Aripiprazole for Bipolar Disorder
4
Exploring CBT Approaches for Chronic Insomnia in Adults: A Systematic Review and Network Meta-Analysis
5
